152 related articles for article (PubMed ID: 34215931)
1. Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.
Kaneda H; Sawa K; Daga H; Okada A; Nakatani Y; Atagi S; Okishio K; Tani Y; Matsumoto Y; Ogawa K; Nakahama K; Izumi M; Mitsuoka S; Kawaguchi T
Invest New Drugs; 2021 Dec; 39(6):1598-1603. PubMed ID: 34215931
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
[TBL] [Abstract][Full Text] [Related]
4. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
[TBL] [Abstract][Full Text] [Related]
5. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Nishio M; Seto T; Reck M; Garon EB; Chiu CH; Yoh K; Imamura F; Park K; Shih JY; Visseren-Grul C; Frimodt-Moller B; Zimmermann A; Homma G; Enatsu S; Nakagawa K;
Cancer Sci; 2020 Dec; 111(12):4510-4525. PubMed ID: 32954593
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated
Yoh K; Atagi S; Reck M; Garon EB; Ponce Aix S; Moro-Sibilot D; Winfree KB; Frimodt-Moller B; Zimmermann A; Visseren-Grul C; Nakagawa K;
Curr Med Res Opin; 2020 Oct; 36(10):1667-1675. PubMed ID: 32780643
[TBL] [Abstract][Full Text] [Related]
7. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
[TBL] [Abstract][Full Text] [Related]
8. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation.
Akamatsu H; Ozawa Y; Oyanagi J; Fujimoto D; Hata A; Katakami N; Tomii K; Murakami E; Sugimoto T; Shimokawa T; Koh Y; Yamamoto N
Anticancer Res; 2021 Feb; 41(2):911-917. PubMed ID: 33517297
[TBL] [Abstract][Full Text] [Related]
10. Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
Haratake N; Hayashi H; Shimokawa M; Nakano Y; Azuma K; Oki M; Ota K; Yoshioka H; Sakamoto T; Yamamoto N; Nakagawa K; Seto T
Clin Lung Cancer; 2022 May; 23(3):e257-e263. PubMed ID: 34887192
[TBL] [Abstract][Full Text] [Related]
11. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
Garon EB; Reck M; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Lee P; Dalal R; Liu J; He S; Treat J; Nakagawa K
Clin Lung Cancer; 2017 Jan; 18(1):96-99. PubMed ID: 27894601
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Goss G; Tsai CM; Shepherd FA; Bazhenova L; Lee JS; Chang GC; Crino L; Satouchi M; Chu Q; Hida T; Han JY; Juan O; Dunphy F; Nishio M; Kang JH; Majem M; Mann H; Cantarini M; Ghiorghiu S; Mitsudomi T
Lancet Oncol; 2016 Dec; 17(12):1643-1652. PubMed ID: 27751847
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
Xing L; Pan Y; Shi Y; Shu Y; Feng J; Li W; Cao L; Wang L; Gu W; Song Y; Xing P; Liu Y; Gao W; Cui J; Hu N; Li R; Bao H; Shao Y; Yu J
Clin Cancer Res; 2020 Dec; 26(23):6168-6175. PubMed ID: 32817079
[TBL] [Abstract][Full Text] [Related]
16. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
Yang JC; Shepherd FA; Kim DW; Lee GW; Lee JS; Chang GC; Lee SS; Wei YF; Lee YG; Laus G; Collins B; Pisetzky F; Horn L
J Thorac Oncol; 2019 May; 14(5):933-939. PubMed ID: 30763730
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.
Boussageon M; Swalduz A; PĂ©rol M
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1071-1080. PubMed ID: 34281470
[TBL] [Abstract][Full Text] [Related]
19. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Nadal E; Horinouchi H; Shih JY; Nakagawa K; Reck M; Garon EB; Wei YF; Kollmeier J; Frimodt-Moller B; Barrett E; Lipkovich O; Visseren-Grul C; Novello S
Drug Saf; 2022 Jan; 45(1):45-64. PubMed ID: 34928484
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]